Allegro Diagnostics

Based in Boston, Massachusetts, Allegro Diagnostics develops molecular diagnostic tests that utilize proprietary gene expression technology to facilitate the early detection of lung cancer. The company's core genomic platform analyzes cytologically normal airway cells obtained through minimally invasive bronchoscopy procedures to help physicians evaluate suspicious lung nodules. This diagnostic approach was validated in prospective, multicenter clinical trials involving 25 medical centers and nearly 1,000 patients across the United States. Prior to its exit, the enterprise secured over $15 million in venture capital financing from institutional backers including Kodiak Venture Partners, Catalyst Health Ventures, and Boston University. In September 2014, the molecular diagnostics firm Veracyte acquired the business for $21 million and subsequently commercialized its flagship technology. Allegro Diagnostics was originally founded in 2006 by academic researchers Jerome Brody, Avrum Spira, and Marc Lenburg.